Shaily Engineering Plastics receives approval for its novel drug delivery device, ShailyPen Neo, marking a significant milestone in their product lineup. Meanwhile, Semaglutide, a popular diabetes treatment, has launched in Canada, with approvals already secured in the US and India.

Shaily Engineering Plastics reported a significant 9% year-on-year increase in Q4 revenue, reaching Rs. 237 crore, and an impressive 26% growth for the entire FY26, totaling Rs. 991 crore. The company's EBITDA margin saw a notable improvement of 420 basis points during this quarter. Additionally, Shaily secured a substantial order worth Rs. 423 crore for pen injectors over the next four years.

Shaily Engineering has reported a significant 20% increase in Q4 EBITDA, reaching ₹656 million. The company's earnings margins have also expanded, now standing at 27.7%. This marks an uptick from the previous year's 25%, demonstrating improved profitability for the quarter.

Shily Engineering Plastics reaches a new record high of Rs 2,847.3 on May 15, 2026, signaling strong and consistent growth in the plastic products industry.

Time Technoplast demonstrates impressive Q3 FY26 results, signaling a strong financial position. Despite certain technical challenges, the company showcases robust operational effectiveness. [Source: Markets Mojo]

Bank of America Securities Europe SA has purchased approximately 237,000 shares of Shaily Engineered Plastics, with an average price of around ₹2419 per share. This investment signifies their continued interest in the company's growth and prospects.

Shaily Engineering's shares surged by 10%, boosted by increasing demand for injector pens, which led to an expansion of production capacity from 80 million to 150 million units. In contrast, Onesource Specialty Pharma experienced a more modest 0.25% rise, as its third-quarter results were lackluster but the company's role in the semaglutide supply chain still provided some support.

Shaily Engineering Plastics has seen a significant investment inflow of INR 1,450 crores from Foreign Institutional Investors (FII) over the past eight quarters, indicating strong business fundamentals and promising growth potential. In the Q3 FY26, the company reported a 27% increase in revenue year-over-year, with the healthcare segment contributing nearly half of its sales.

Shaly Engineering shares dropped by 14% due to increased raw material costs in West Asia, putting pressure on margins. In response, the company is planning to establish a new AED 130-150 million medical device facility in Abu Dhabi to expand its global reach by Q4 FY28.

Shaily Engineering Plastics is addressing capacity constraints due to increased demand for GLP-1 and semaglutide devices by planning an expansion. The Abu Dhabi facility will boost production capacity by 75 million units annually, expected by Q4 FY28. However, potential geopolitical risks may affect the execution timeline.